| Type | Monograph |
| Title | “Economic Reforms, WTO and Indian Drugs and Pharmaceuticals Industry: Implications of Emerging Trends” |
| Authors | Nagesh Kumar & Jaya Prakash Pradhan |
| Published | 2003 · CMDR Monograph Series No. 42 · Centre for Multidisciplinary Development Research, Dharwad |
| Focus | How patent and price policy built India’s pharma industry — and what TRIPS could change |
| Read | Monograph (PDF) |
This is a plain-language summary of “Economic Reforms, WTO and Indian Drugs and Pharmaceuticals Industry: Implications of Emerging Trends” (Kumar & Pradhan, CMDR Monograph No. 42, 2003).
In short:
- A deliberate policy mix — process (not product) patents, price controls, and support for domestic R&D — turned India from an import-dependent country into the “pharmacy of the world.”
- The same shift to product patents under the WTO’s TRIPS agreement threatened the affordability that made that industry matter: the study cites estimates of drug-price rises ranging from 26% to 242%.
- The authors argue India can preserve its dual role — competitive industry and affordable-medicine supplier — but only through deliberate policy: more R&D, niche strengths, and careful use of TRIPS flexibilities.
From import dependence to “pharmacy of the world”
In the 1970s, most medicines in India were imported and expensive. By the early 2000s, India was supplying affordable generic drugs to much of the world. This monograph, by Nagesh Kumar and Jaya Prakash Pradhan, explains that this was not an accident of the market but the product of deliberate policy — and then asks what the WTO-era shift to stronger patents would do to it.
What built the industry
The transformation rested on an integrated set of policy choices, and the single most important was a particular approach to patents.
The crucial move was the 1970 Patent Act’s recognition of process patents but not product patents: a medicine’s molecule couldn’t be monopolised, only a specific method of making it. That gave Indian firms the legal room to become masters of process innovation — finding new, cheaper ways to manufacture existing drugs. (The study illustrates the payoff with striking comparisons, noting Indian-made medicines priced a small fraction of Western levels.) Combined with price controls to keep medicines affordable, incentives for domestic manufacturing, and support for R&D, this built a robust indigenous industry that came to export to dozens of countries — and played a real role in global health, including making HIV/AIDS treatments affordable in Africa.
What put it at a crossroads
The monograph’s central tension is that the very rules being introduced to reward innovation threatened the access that defined India’s pharma success.
Under the WTO’s TRIPS agreement, India had to move from process to product patents, alongside reduced price controls and more open competition. The worry the study foregrounds is affordability: it cites empirical estimates that drug prices could rise anywhere from 26% to 242% once product patents took hold. The range is wide — it depends heavily on assumptions and which drugs — but every estimate points the same direction, toward significantly costlier patented medicines and the risk of putting some essential drugs out of reach. Compounding the challenge, India’s domestic R&D intensity remained low — around 1.55% — modest by the standards of research-driven global pharma, which mattered because a product-patent world rewards original innovation rather than process ingenuity.
The way forward
The authors’ conclusion is not fatalistic. They argue India’s pharma sector can preserve its dual role — a competitive industry and a provider of affordable medicines — but only through deliberate strategy: stepping up R&D investment, building on niche strengths (including traditional medicine), forming selective global partnerships, protecting capable domestic firms, and — importantly — making careful use of the flexibilities built into TRIPS (such as compulsory licensing) to safeguard access to essential drugs. The larger argument, and the reason the monograph still reads well, is that India’s experience is a model for how a developing country can build an industry that serves both economic and social goals — and that keeping that balance through the patent transition was a matter of policy choice, not fate.
Read the academic abstract
This paper examines the evolution and transformation of India’s pharmaceutical industry in the context of economic reforms, WTO commitments, and changing patent regulations. Through analysis of historical policy frameworks, industry data, and emerging trends, it investigates how India developed from an import-dependent nation into a global leader in pharmaceutical production and exports. The study shows that an integrated policy approach — combining process-patent protection, price controls, and support for domestic R&D — enabled India to build robust indigenous capabilities in pharmaceutical manufacturing. However, it finds that recent policy shifts, including TRIPS-compliance requirements and economic liberalisation, pose significant challenges: empirical estimates suggest potential drug-price increases of 26–242% following product-patent implementation, while domestic R&D intensity remains relatively low at about 1.55% by global standards. The paper evaluates strategic options for sustaining competitiveness while maintaining affordable access — strengthened R&D investment, traditional-medicine opportunities, and strategic use of TRIPS flexibilities — and concludes that carefully crafted policies balancing innovation and access could preserve the industry’s dual role as a competitive sector and a provider of affordable medicines. It contributes to broader debates on industrial policy, intellectual property rights, and public health in developing economies.Cite this monograph
Kumar, N., & Pradhan, J. P. (2003). Economic reforms, WTO and Indian drugs and pharmaceuticals industry: Implications of emerging trends (CMDR Monograph Series No. 42). Dharwad: Centre for Multidisciplinary Development Research.
Related on this site
- How stronger patents affected India’s pharma exports: Growing Global: How Stronger Patent Laws Boosted India’s Pharmaceutical Exports
- Whether foreign presence lifted local pharma productivity: The FDI Effect: A Story of India’s Pharmaceutical Productivity
- How firm size and reforms shaped pharma innovation: The Innovation Race: How Enterprise Size & Policy Shape India’s Pharmaceutical Future
